Key to Helping Central Sleep Apnea Patients Stay on Therapy Published in the Journal of Clinical Sleep Medicine
22 percent more CSA patients are adherent on ASV vs. PAP, says ResMed-funded study

SAN DIEGO – January 24, 2018 – Switching from positive airway pressure (PAP) to adaptive servo ventilation (ASV) therapy can help patients with central sleep apnea be more adherent on therapy, according to a ResMed-funded study published in the Journal of Clinical Sleep Medicine (JCSM).

The study analyzed anonymous, aggregated data from the devices of 198,890 telemonitored U.S. patients with treatment-emergent central sleep apnea who started on PAP therapy, and found that:

  • 62.7 percent of patients were adherent on therapy while still on PAP; and
  • 76.6 percent of patients were adherent after switching to ASV therapy (a 22 percent relative increase)

JCSM’s publication is a significant call for clinicians to monitor sleep apnea patients for central apneas and prescribe the therapy that best fits their needs,” said Carlos M. Nunez, M.D., ResMed’s Chief Medical Officer.

The study was first presented in April 2017 at the Sleep and Breathing Conference in Marseilles, France. Read the study:

About ResMed

ResMed (NYSE: RMD, ASX: RMD) changes lives with award-winning medical devices and cloud-based software applications that better diagnose, treat and manage sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed is a global leader in connected care, with more than 4 million patients remotely monitored every day. Our 6,000-strong team is committed to creating the world’s best tech-driven medical device company – improving quality of life, reducing the impact of chronic disease, and saving healthcare costs in more than 120 countries.

# # #

Media contacts - Bottom Blue - All Interior Pages

Media contact

Jayme Rubenstein
(858) 836-6798


Receive ResMed news releases when they publish.


ResMed provides a non-transferable, non-exclusive license to the copyrighted images, drawings and materials subject to the following Terms of Use.

All countries & languages